A Study to Evaluate the Safety, Tolerability, and Drug Levels of Danicamtiv in Healthy Japanese and Caucasian Participants

Launched by BRISTOL-MYERS SQUIBB · Mar 29, 2023

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Body mass index between 18 and 30 kilograms/meter squared inclusive, at the screening visit.
• • Japanese participants must be of Japanese descent (both biological parents are ethnically Japanese).
• • Caucasian participants must be of European or Latin American Caucasian descent.
• • A female participant is eligible to participate if she is a woman of nonchildbearing potential as defined in the protocol.
• • Males who are sexually active with woman of childbearing potential must agree to follow protocol-defined instructions for method(s) of contraception.
• Exclusion Criteria:
• • Any acute or chronic medical illness.
• • Active infection, including with coronavirus disease-19, diagnosed clinically by the investigator.
• • History of any other clinically significant disorder, condition, or disease that, in the opinion of the investigator or sponsor clinical trial physician, would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion.
• • Note: Other protocol-defined inclusion/exclusion criteria apply.